Eli Lilly and Company (NYSE: LLY) announced it will present data from its Phase 3 EMBER-3 trial for imlunestrant, an oral selective estrogen receptor degrader (SERD), at the San Antonio Breast Cancer Symposium (SABCS) from December 10-13. This late-breaking presentation marks the first time EMBER-3 data will be publicly shared. EMBER-3 is evaluating imlunestrant as a monotherapy or combined with Verzenio (abemaciclib) in patients with ER+, HER2- advanced breast cancer who have undergone prior endocrine therapy, with or without a CDK4/6 inhibitor.

Detailed Insights

The EMBER-3 trial, centered on patients with estrogen receptor positive, HER2- advanced breast cancer, assesses the efficacy of imlunestrant, which could become a significant advancement in treatment options. The trial studies imlunestrant used both as a standalone therapy and alongside Verzenio, Lilly’s established CDK4/6 inhibitor. Verzenio, already approved for certain HR+, HER2- breast cancers in various stages, has set a strong precedent in both the adjuvant and metastatic settings.

Lilly’s presence at SABCS will also include the release of real-world analysis on recurrence risk by nodal status and high-risk features in HR+, HER2- early breast cancer patients. Additionally, data related to PI3Ka inhibitors, such as the preclinical findings of LY4045004 expected to enter clinical trials in 2025 and Phase 1a/b results of its predecessor, LOXO-783, will be presented.

Expert Insights on Verzenio’s Significance

Experts have highlighted Verzenio’s clinical differentiation within the CDK4/6 inhibitor class. The drug has shown persistent benefits, particularly in high-risk early breast cancer, as evidenced by data from the monarchE trial, which demonstrated continued efficacy beyond the initial two-year treatment window. Verzenio’s Phase 3 MONARCH 2 study showcased its ability to extend overall survival in metastatic breast cancer patients, further solidifying its role as a reliable treatment option.

Verzenio is available as an oral tablet taken twice daily, with dosage options of 50 mg, 100 mg, 150 mg, and 200 mg. Its manageable safety profile, demonstrated in clinical trials, has contributed to its global approval across more than 90 countries since its initial authorization in 2017.

Lilly’s comprehensive approach to advancing breast cancer treatment through rigorous clinical programs like EMBER-3 and continuous real-world data analysis underlines its commitment to improving patient outcomes. The inclusion of investigational assets such as LY4045004 showcases the company’s ongoing innovation within the oncology space.

  Eli Lilly and Company, EMBER-3, Imlunestrant, LOXO-783, LY4045004, MONARCH 2, monarchE, NCCN, SABCS, San Antonio, Verzenio